Navigation Links
Common Weight-Loss Surgery May Double Risk of Kidney Stones
Date:6/22/2009

Roux-en-Y gastric bypass linked to small increased chances of trouble, research shows

MONDAY, June 22 (HealthDay News) -- A popular weight-loss surgery may double the risk of kidney stones, though the actual odds are still relatively slight, a new study suggests.

Having Roux-en-Y, the most common type of gastric bypass surgery, may result in a person having an 8 percent chance of developing the urinary tract disorder usually caused by oxalate in food combining with calcium or other chemicals to form clusters of crystals. These stones can be very painful to pass through normal urination and sometimes require surgery or other medical intervention to treat.

In Roux-en-Y surgery, surgical connections around the bowel help decrease stomach capacity and let food bypass part of the small intestine. The surgery, used to treat obesity, had previously been thought not to cause issues with calcium absorption or kidney stones as had previously been shown with other types of bariatric surgery.

"Our study is not an indictment of bariatric surgery -- the benefits of this surgery are well-known," lead researcher Dr. Brian Matlaga, an assistant professor of urology at the Johns Hopkins Medical Institutions, said in a news release from Hopkins. "Rather, we'd like to help physicians understand that their bariatric patients could be at risk for kidney stones, a condition that could be avoidable with proper preventative care."

He said that Roux-en-Y surgery, like other weight-loss procedures, might reduce the amount of calcium that patients absorb and adding calcium supplements may help cut the kidney stone risk.

The findings, appearing in the June issue of the Journal of Urology, reached its conclusions based on insurance claims of more than 4,600 people who had Roux-en-Y surgery between 2002 and 2006 compared to the same number of obese people with similar demographics who did not have the procedure done.
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Skin and Skin Structure Infections Are the Second Most Common Diagnoses for Which an Antibiotic Is Used in the Hospital Setting
2. Pesticide Residue Common on Kitchen Floors
3. STAAR Surgical Completes Common Stock Offering
4. BioMed Realty Trust Declares Second Quarter 2009 Common Stock and Preferred Stock Dividends
5. USHairReplacement.com Provides Wealth of Knowledge to Common Hair Replacement Questions
6. UNC study suggests new approach to common cause of blindness
7. Fatigue common after myocardial infarction
8. Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering
9. DATATRAK Announces Receipt of NASDAQ Panel Decision to Delist Common Shares
10. Common diabetes drug may revolutionize cancer therapies
11. HealthEdge(R) and Click4Care(R) Announce Common Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Common Weight-Loss Surgery May Double Risk of Kidney Stones
Common Weight-Loss Surgery May Double Risk of Kidney Stones
Other Medicine News:Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:CoorsTek Holds Grand Opening for Newest Facility in South Korea 2Health News:CoorsTek Holds Grand Opening for Newest Facility in South Korea 3Health News:Don't Wait for the Election to Plan Your Long-Term Healthcare, Insurance Leader Advises 2Health News:Chemo for Mesothelioma Offers Limited Survival Benefits 2Health News:dLife Launches the World's Largest and Most Comprehensive Online Food and Diabetic Recipe Search Tool 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Express Scripts Launches Equity Offering to Finance Acquisition 47588 1Express Scripts Launches Equity Offering to Finance Acquisition 47588 2Express Scripts Launches Equity Offering to Finance Acquisition 47588 3Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 1Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 2Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 3Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 4Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 5Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 1Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 2Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 3
Other Medicine Technology:Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 2Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 3Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 4Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 5Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5